Reference
Aykan, N. F. and T. Özatlı (2020). "Objective response rate assessment in oncology: Current situation and future expectations." World J Clin Oncol 11(2): 53-73.
Berry, V., L. Basson, E. Bogart, O. Mir, J. Y. Blay, A. Italiano, F. Bertucci, C. Chevreau, S. Clisant-Delaine, B. Liegl-Antzager, E. Tresch-Bruneel, J. Wallet, S. Taieb, E. Decoupigny, A. Le Cesne, T. Brodowicz and N. Penel (2017). "REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis." Cancer 123(12): 2294-2302.
Borcoman, E., A. Nandikolla, G. Long, S. Goel and C. Le Tourneau (2018). "Patterns of Response and Progression to Immunotherapy." Am Soc Clin Oncol Educ Book 38: 169-178.
Chi, Y., Z. Fang, X. Hong, Y. Yao, P. Sun, G. Wang, F. Du, Y. Sun, Q. Wu, G. Qu, S. Wang, J. Song, J. Yu, Y. Lu, X. Zhu, X. Niu, Z. He, J. Wang, H. Yu and J. Cai (2018). "Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma." Clin Cancer Res 24(21): 5233-5238.
Choi, J. H., M. J. Ahn, H. C. Rhim, J. W. Kim, G. H. Lee, Y. Y. Lee and I. S. Kim (2005). "Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma." Cancer Res Treat 37(5): 290-293.
D'Angelo, S. P., M. R. Mahoney, B. A. Van Tine, J. Atkins, M. M. Milhem, B. N. Jahagirdar, C. R. Antonescu, E. Horvath, W. D. Tap, G. K. Schwartz and H. Streicher (2018). "Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials." Lancet Oncol 19(3): 416-426.
Eulo, V. and B. A. Van Tine (2022). "Immune checkpoint inhibitor resistance in soft tissue sarcoma." Cancer Drug Resist 5(2): 328-338.
Fukumura, D., J. Kloepper, Z. Amoozgar, D. G. Duda and R. K. Jain (2018). "Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges." Nat Rev Clin Oncol 15(5): 325-340.
George, S., P. Merriam, R. G. Maki, A. D. Van den Abbeele, J. T. Yap, T. Akhurst, D. C. Harmon, G. Bhuchar, M. M. O'Mara, D. R. D'Adamo, J. Morgan, G. K. Schwartz, A. J. Wagner, J. E. Butrynski, G. D. Demetri and M. L. Keohan (2009). "Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas." J Clin Oncol 27(19): 3154-3160.
Hashimoto, K. (2021). "CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development." Cancers (Basel) 13(10).
Kim, S. K., J. H. Kim, S. H. Kim, Y. H. Lee, J. W. Han, W. Baek, H. Y. Woo, M. K. Jeon and H. S. Kim (2021). "PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma." BMC Cancer 21(1): 336.
Martin-Broto, J., N. Hindi, G. Grignani, J. Martinez-Trufero, A. Redondo, C. Valverde, S. Stacchiotti, A. Lopez-Pousa, L. D'Ambrosio, A. Gutierrez, H. Perez-Vega, V. Encinas-Tobajas, E. de Alava, P. Collini, M. Peña-Chilet, J. Dopazo, I. Carrasco-Garcia, M. Lopez-Alvarez, D. S. Moura and J. A. Lopez-Martin (2020). "Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial." J Immunother Cancer 8(2).
Ocadlikova, D., M. Lecciso, J. M. Broto, K. Scotlandi, M. Cavo, A. Curti and E. Palmerini (2021). "Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade." Front Immunol 12: 577766.
Petitprez, F., A. de Reyniès, E. Z. Keung, T. W. Chen, C. M. Sun, J. Calderaro, Y. M. Jeng, L. P. Hsiao, L. Lacroix, A. Bougoüin, M. Moreira, G. Lacroix, I. Natario, J. Adam, C. Lucchesi, Y. H. Laizet, M. Toulmonde, M. A. Burgess, V. Bolejack, D. Reinke, K. M. Wani, W. L. Wang, A. J. Lazar, C. L. Roland, J. A. Wargo, A. Italiano, C. Sautès-Fridman, H. A. Tawbi and W. H. Fridman (2020). "B cells are associated with survival and immunotherapy response in sarcoma." Nature 577(7791): 556-560.
Rabinovich, G. A., D. Gabrilovich and E. M. Sotomayor (2007). "Immunosuppressive strategies that are mediated by tumor cells." Annu Rev Immunol 25: 267-296.
Tawbi, H. A., M. Burgess, V. Bolejack, B. A. Van Tine, S. M. Schuetze, J. Hu, S. D'Angelo, S. Attia, R. F. Riedel, D. A. Priebat, S. Movva, L. E. Davis, S. H. Okuno, D. R. Reed, J. Crowley, L. H. Butterfield, R. Salazar, J. Rodriguez-Canales, A. J. Lazar, Wistuba, II, L. H. Baker, R. G. Maki, D. Reinke and S. Patel (2017). "Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial." Lancet Oncol 18(11): 1493-1501.
Weiss, A. R., Y. L. Chen, T. J. Scharschmidt, Y. Y. Chi, J. Tian, J. O. Black, J. L. Davis, J. C. Fanburg-Smith, E. Zambrano, J. Anderson, R. Arens, O. Binitie, E. Choy, J. W. Davis, A. Hayes-Jordan, S. C. Kao, M. L. Kayton, S. Kessel, R. Lim, W. H. Meyer, L. Million, S. H. Okuno, A. Ostrenga, M. T. Parisi, D. A. Pryma, R. L. Randall, M. A. Rosen, M. Schlapkohl, B. L. Shulkin, E. A. Smith, J. I. Sorger, S. Terezakis, D. S. Hawkins, S. L. Spunt and D. Wang (2020). "Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial." Lancet Oncol 21(8): 1110-1122.
Wilky, B. A., M. M. Trucco, T. K. Subhawong, V. Florou, W. Park, D. Kwon, E. D. Wieder, D. Kolonias, A. E. Rosenberg, D. A. Kerr, E. Sfakianaki, M. Foley, J. R. Merchan, K. V. Komanduri and J. C. Trent (2019). "Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial." Lancet Oncol 20(6): 837-848.
Yang, J., J. Yan and B. Liu (2018). "Targeting VEGF/VEGFR to Modulate Antitumor Immunity." Front Immunol 9: 978.
You, Y., X. Guo, R. Zhuang, C. Zhang, Z. Wang, F. Shen, Y. Wang, W. Liu, Y. Zhang, W. Lu, Y. Hou, J. Wang, X. Zhang, M. Lu and Y. Zhou (2021). "Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis." Frontiers in Molecular Biosciences 8.